The Company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other unmet medical needs.


Updates from The Motley Fool

Latest updates on Sunesis Pharmaceuticals from Fool.com.
3 Biotechs Burning Through Cash

Investors would be wise to know how biotech companies are spending that cash on hand while they d...

3 Winners From QE3

These stocks just took off, but are they about to make a return trip to Earth?

3 Top Stocks at Half-Price

Investors still think highly of these companies, despite their fire-sale prices.



Stock Performance

View Interactive SNSS Charts
Sponsored by

Key Data Points

Primary metrics and data points about Sunesis Pharmaceuticals.
Current Price: $2.15
Prev Close: $2.17
Open: $2.17
Bid: $2.03
Ask: $2.47
Day's Range: $2.15 - $2.33
52wk Range: $2.14 - $6.30
Volume: 31,496
Avg Vol 59,086
Market Cap: $51M
P/E (ttm): -1.17
EPS (ttm): ($1.86)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Sunesis Pharmaceuticals.
CAPS Rating 1 out of 5
 
82 Outperform
24 Underperform
CAPS All Stars
 
21 Outperform
15 Underperform

How do you think Sunesis Pharmaceuticals will perform against the market?



You pick for Sunesis Pharmaceuticals is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Dan Swisher Jr., CEO

82% Approve

Based on 4 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Sunesis Pharmaceuticals.

The Company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other unmet medical needs.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers